The world has started facing a dramatic change in global health challenges. On top of the unmet needs to
combat communicable diseases especially in the developing world our societies become larger, older and unhealthier. We even export most of these life style diseases into the low and most prominently the medium income countries (LMIC). 2/3 of all new cancer cases in 2030 can be estimated to be diagnosed in LMIC, the highest increase in type 2 diabetes and glucose intolerance will be seen in LMICs. At the same time public health spending is increasing already and the need for an economic return for Pharma is becoming shorter. For big Innovations first stage funding is seen as too risky and seed funding instruments are unattractive for investors.
Healthcare systems have no proper solutions in place to cope with the upcoming health challenges and
countries have no strategy how to finance healthcare under these expected developments. This situation will result in a major threat for global economy. There is a need for new solutions for better prevention of diseases and more efficient cures. These solutions have to emerge from top level research requiring also new financing instruments to enable efficient translation of research into innovation.
